MedXY News
EnglishTagOral Semaglutide
7 all articles · 20 / page
Ask MedXY AI
Latest news
Tag
EN
Oral Semaglutide and Cardiovascular Benefits in the SOUL Trial: Impact of Baseline and Changes in HbA1c and BMI on Clinical Outcomes
This analysis of the SOUL trial shows oral semaglutide reduces major cardiovascular events, with greater benefits linked to higher baseline HbA1c and larger HbA1c reductions, while BMI changes did not significantly affect outcomes.
Section: CardiologyJul 22, 2026
EN
Oral Semaglutide and Cardiovascular Risk Factor Changes in High-Risk Type 2 Diabetes
Oral semaglutide improved multiple cardiovascular risk factors in high-risk type 2 diabetes, including HbA1c, weight, systolic blood pressure, inflammation, and some lipid measures, with benefits sustained over nearly four years.
